Race Oncology Ltd executive director and chairman Dr Peter Smith talked with Proactive about securing more than A$3.22 million via a private placement to fund the HARNESS-1 Phase 1a/b clinical trial.
The total trial cost is expected to be A$11.5 million, and Race Oncology is now in a position to fully fund the study.
Ethics approval has been granted, and only a few institutional approvals remain before the first patient can be enrolled in early Q1 of next calendar year.
For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications so you never miss an update.
#RaceOncology #RC220 #LungCancer #EGFRInhibitor #Tagrisso #Osimertinib #CancerResearch #BiotechNews #ClinicalTrials #ProactiveInvestors #ASXRAC